Cargando…

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

BACKGROUND: Bleeding is a clinically significant issue with all current anticoagulants. Safer antithrombotic strategies are required. OBJECTIVES: To investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, a humanized, factor XI (FXI)‐directed monoclonal antibody, after single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowotny, Bettina, Thomas, Dirk, Schwers, Stephan, Wiegmann, Sara, Prange, Wolfgang, Yassen, Ashraf, Boxnick, Stefanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320929/ https://www.ncbi.nlm.nih.gov/pubmed/35490404 http://dx.doi.org/10.1111/jth.15744

Ejemplares similares

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
por: Thomas, Dirk, et al.
Publicado: (2019)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case‐control study
por: Chen, Huiting, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study
por: Kubitza, Dagmar, et al.
Publicado: (2022)

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
por: Li, Chan, et al.
Publicado: (2019)

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen
por: Bar Barroeta, Awital, et al.
Publicado: (2022)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays
por: Liang, Yideng, et al.
Publicado: (2020)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study
por: Handa, Shivani, et al.
Publicado: (2022)

Cryo-EM structure of coagulation factor V short
por: Mohammed, Bassem M., et al.
Publicado: (2023)

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing
por: Gosselin, Robert C., et al.
Publicado: (2021)

Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo
por: Chen, Zu-Lin, et al.
Publicado: (2022)

Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia
por: Hisada, Yohei, et al.
Publicado: (2023)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
por: Donkor, David A., et al.
Publicado: (2017)

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
por: Childers, Kenneth C., et al.
Publicado: (2023)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex
por: Gierula, Magdalena, et al.
Publicado: (2019)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Factor VIII as a potential player in cancer pathophysiology
por: Walker, Gillian E., et al.
Publicado: (2022)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Profiling of warfarin pharmacokinetics‐associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics‐dosing algorithm
por: Ndadza, Arinao, et al.
Publicado: (2021)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease
por: Badimon, Juan J., et al.
Publicado: (2022)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
por: Yasaka, Masahiro, et al.
Publicado: (2017)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Properdin (factor P) as a new target cleaved by factor XIa: Intrinsic coagulation at the crossroads with inflammation
por: Luo, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d18a60divsgmsui46bfm18k4fj